Mechanisms for delaying epiphyseal fusion and improving adult height in pubertal patients with hypopituitarism

Research output: Contribution to journalReview article

1 Scopus citations

Abstract

The preservation of linear growth potential is on important goal for many patients presenting to the pediatric endocrine clinic. This is particularly true for pubertal adolescents with growth hormone deficiency who are diagnosed late and for short children with hypopituitarism and central precocious puberty, a combination that confers a poor prognosis for adult stature. In this review, currently available and promising new strategies for delaying epiphyseal fusion and increasing adult height in pubertal patients are discussed. White GnRH analogues are the standard of care for treating central precocious puberty, concerns exist regarding adverse metabolic effects of these agents when used in adolescence. Alternate approaches that diminish epiphyseal estrogen exposure yet allow pubertal development to progress in boys include antiestrogens in the form of aromatase inhibitors and estrogen receptor antagonists. Data from clinical trials using these compounds in a variety of pediatric conditions are summarized, and future directions are identified.

Original languageEnglish (US)
Pages (from-to)301-305
Number of pages5
JournalPediatric Endocrinology Reviews
Volume3
Issue numberSUPPL. 2
StatePublished - Apr 1 2006

    Fingerprint

Keywords

  • Antiestrogens
  • Growth Hormone
  • Height
  • Puberty

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Endocrinology, Diabetes and Metabolism
  • Internal Medicine

Cite this